title: Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer.
abstract: Antiphospholipid antibodies (aPL) have been suggested to play a role in causing cognitive and behavioral impairments. In the present study we investigated the pathogenic potential of aPL by intracerebro-ventricular (ICV) administration of immunoglobulins (IgG) from patients with antiphospholipid syndrome (APS). IgG, purified from the sera of four APS patients, was tested for binding to normal mouse brain by immunohistological staining. These IgG (7.5 microg) were injected ICV unilaterally to male C3H mice. Mice injected with IgG purified from pooled sera derived from healthy subjects served as controls. The mice were examined neurologically for motor function and coordination, and cognitively in a Morris water maze. The cognitive tests were performed with the experimenter blinded to the treatment. The performance of the mice in four separate experiments was compared by analysis of variance with repeated measures. IgG from one APS patient was found to bind best to neuronal structures in the hippocampus and cerebral cortex. Mice (n = 43) injected with this IgG performed worse in the water maze compared to the controls (n = 45) with significant effects of the aPL IgG on the overall performance of the mice (treatment, P < 0.03), on learning throughout the experiment (treatment x day, P < 0.02) and on short term memory (treatment x day xtrial, P < 0.002). IgG injected from two of the three other patients also bound specifically to mouse brain neurons and produced an impairment in performance of the water maze. These results support the hypothesis that aPL that gain access to the central nervous system may play a direct role in the pathogenesis of neurological manifestations of APS.
authors.affiliation: Department of Medicine B and Research Center for Autoimmune Diseases,Sheba MedicalCenter, Tel Hashomer, Israel. shoenfel@post.tau.ac.il
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
authors.forename: A
authors.initials: A
authors.lastname: Nahum
authors.forename: A D
authors.initials: AD
authors.lastname: Korczyn
authors.forename: M
authors.initials: M
authors.lastname: Dano
authors.forename: R
authors.initials: R
authors.lastname: Rabinowitz
authors.forename: O
authors.initials: O
authors.lastname: Beilin
authors.forename: C G
authors.initials: CG
authors.lastname: Pick
authors.forename: L
authors.initials: L
authors.lastname: Leider-Trejo
authors.forename: L
authors.initials: L
authors.lastname: Kalashnikova
authors.forename: M
authors.initials: M
authors.lastname: Blank
authors.forename: J
authors.initials: J
authors.lastname: Chapman
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000818:Animals; D017152:Antibodies, Antiphospholipid / Q000009:adverse effects*; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications*; D001707:Biopsy, Needle; D001921:Brain / Q000473:pathology; D016022:Case-Control Studies; D003072:Cognition Disorders / Q000209:etiology / Q000276:immunology* / Q000473:pathology*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology*; D007150:Immunohistochemistry; D007278:Injections, Spinal; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D011336:Probability; D011379:Prognosis; D012307:Risk Factors; D012680:Sensitivity and Specificity
chemical_list: D017152:Antibodies, Antiphospholipid; D007074:Immunoglobulin G